Auris Medical is developing novel pharmaceutical products for the treatment of inner ear disorders.
We are focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1.
In addition Auris Medical has two Phase 3 programs under development: AM-111 for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. AM-111 has been granted orphan drug status by the FDA and the EMA.
1) Dates of key milestones are indicative and subject to change.
ASNHL: Acute Sensorineural Hearing Loss; FPI: First Patient In.